Mirum Pharmaceuticals Inc
NASDAQ:MIRM

Watchlist Manager
Mirum Pharmaceuticals Inc Logo
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
Watchlist
Price: 44.73 USD 2.87% Market Closed
Market Cap: 2.1B USD
Have any thoughts about
Mirum Pharmaceuticals Inc?
Write Note

Mirum Pharmaceuticals Inc
Intangible Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Mirum Pharmaceuticals Inc
Intangible Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Intangible Assets CAGR 3Y CAGR 5Y CAGR 10Y
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
Intangible Assets
$252.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Intangible Assets
$66.6B
CAGR 3-Years
-5%
CAGR 5-Years
28%
CAGR 10-Years
46%
Gilead Sciences Inc
NASDAQ:GILD
Intangible Assets
$20.5B
CAGR 3-Years
-15%
CAGR 5-Years
7%
CAGR 10-Years
6%
Amgen Inc
NASDAQ:AMGN
Intangible Assets
$28.9B
CAGR 3-Years
25%
CAGR 5-Years
34%
CAGR 10-Years
8%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Intangible Assets
$831.6m
CAGR 3-Years
28%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Intangible Assets
$1.1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Mirum Pharmaceuticals Inc
Glance View

Market Cap
2.1B USD
Industry
Biotechnology

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Foster City, California and currently employs 137 full-time employees. The company went IPO on 2019-07-18. The firm is focused on the identification, acquisition, development, and commercialization of therapies for rare and orphan diseases. The firm's main focus is the development and commercialization of LIVMARLI (maralixibat) oral solution (Livmarli) and Volixibat. Its pipeline consists of rare pediatric indications for Livmarli and orphan adult indications for its second product candidate, Volixibat. Livmarli is an oral solution as a once-daily medicine for cholestatic pruritus in patients with Alagille syndrome (ALGS) one year of age and older. Volixibat, is an oral, minimally absorbed agent designed to inhibit ileal bile acid transporter (IBAT), for the treatment of adult patients with cholestatic liver diseases. The firm is developing volixibat for the treatment of intrahepatic cholestasis of pregnancy (ICP), primary sclerosing cholangitis (PSC), and primary biliary cholangitis (PBC).

MIRM Intrinsic Value
44.8 USD
Fairly Valued
Intrinsic Value
Price

See Also

What is Mirum Pharmaceuticals Inc's Intangible Assets?
Intangible Assets
252.9m USD

Based on the financial report for Dec 31, 2023, Mirum Pharmaceuticals Inc's Intangible Assets amounts to 252.9m USD.

What is Mirum Pharmaceuticals Inc's Intangible Assets growth rate?
Intangible Assets CAGR 1Y
329%

Over the last year, the Intangible Assets growth was 329%.

Back to Top